Valsartan/Hydrochlorothiazide ratiopharm 80 mg/12,5 mg Filmdragerad tablett

Land: Sverige

Sprog: svensk

Kilde: Läkemedelsverket (Medical Products Agency)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
22-04-2018
Produktets egenskaber Produktets egenskaber (SPC)
28-04-2018

Aktiv bestanddel:

hydroklortiazid; valsartan

Tilgængelig fra:

ratiopharm GmbH

ATC-kode:

C09DA03

INN (International Name):

hydrochlorothiazide; valsartan

Dosering:

80 mg/12,5 mg

Lægemiddelform:

Filmdragerad tablett

Sammensætning:

hydroklortiazid 12,5 mg Aktiv substans; valsartan 80 mg Aktiv substans

Klasse:

Apotek

Recept type:

Receptbelagt

Terapeutisk område:

Valsartan och diuretika

Produkt oversigt:

Förpacknings: Blister, 14 tabletter; Burk, 100 tabletter; Blister, 20 tabletter; Blister, 28 tabletter; Blister, 30 tabletter; Blister, 56 tabletter; Blister, 60 tabletter; Blister, 90 tabletter; Blister, 98 tabletter; Blister, 100 tabletter; Blister, 280 tabletter; Burk, 500 tabletter

Autorisation status:

Godkänd

Autorisation dato:

2010-02-26

Indlægsseddel

                                1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Valsartan/Hydrochlorothiazide ratiopharm 80 mg/12.5 mg film-coated
tablets
Valsartan/Hydrochlorothiazide ratiopharm 160 mg/12.5 mg film-coated
tablets
Valsartan/Hydrochlorothiazide ratiopharm 160 mg/25 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 80 mg valsartan and 12.5 mg
hydrochlorothiazide.
Each film-coated tablet contains 160 mg valsartan and 12.5 mg
hydrochlorothiazide.
Each film-coated tablet contains 160 mg valsartan and 25 mg
hydrochlorothiazide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
80 mg/12.5 mg: Light orange, oval shaped film-coated tablet
(dimension: approx. 5.3 x 10.2
mm).
160 mg/12.5 mg: Dark-red, oval shaped film-coated tablets (dimension:
approx. 6.1 x 15.2 mm).
160 mg/25 mg: Brown, oval shaped, film-coated tablet, scored on one
side (dimension: approx.
5.6 x 14.2 mm).
The tablet can be divided into equal doses.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension in adults.
_Valsartan/Hydrochlorothiazide ratiopharm_ is indicated in patients
whose blood pressure is not
adequately controlled on valsartan or hydrochlorothiazide monotherapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose of _Valsartan/Hydrochlorothiazide ratiopharm _is
one film-coated tablet
once daily. Dose titration with the individual components is
recommended. In each case, up-
titration of individual components to the next dose should be followed
in order to reduce the
risk of hypotension and other adverse events.
When clinically appropriate direct change from monotherapy to the
fixed combination may be
considered in patients whose blood pressure is not adequately
controlled on valsartan or
hydrochlorothiazide monotherapy, provided the recommended dose
titration sequence for the
individual components is followed.
2
The clinical response to _Valsartan/Hydrochlorothiazide ratiopharm
_should be e
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                MARKNADSFÖRS EJ FÖR NÄRVARANDE.
_Produktinformation_
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel engelsk 04-05-2022
Produktets egenskaber Produktets egenskaber engelsk 04-05-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport engelsk 21-02-2013